10-K · July 22, 2026
Alzamend remains a pre-revenue, clinical-stage biotechnology company with $0 revenue in FY2026 and an $8.77 million net loss, up from a $4.51 million loss in FY2025. Its central strategic value proposition is…
Earnings analysis · 10-Q
ALZN earnings analysis
Filed September 10, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include income-statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so no operating trend can be assessed. The principal disclosure is that internal control…
Read full summary
The provided 10-Q excerpt does not include income-statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so no operating trend can be assessed. The principal disclosure is that internal control over financial reporting remained ineffective because a previously identified material weakness had not been remediated. Management continued remediation efforts, but stated that limited resources and future accounting-department expansion are required; the filing otherwise reports no material legal proceedings and no material change in controls during the quarter ended July 31, 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Financial statements deemed fairly presented
Management stated that the condensed financial statements for the periods presented fairly present the company's financial condition, results of operations, and cash flows in conformity with U.S. GAAP, despite the identified control deficiency.
-
No quarterly control change reported
The company reported no material change in internal control over financial reporting during the quarter ended July 31, 2026.
-
Remediation plan remains active
The company said it is continuing remediation through formalized internal-control documentation and stronger management supervisory reviews; remediation is not complete until controls operate effectively for a sufficient period and testing is concluded.
-
No material litigation identified
The company reported that it was not currently party to or aware of any legal proceedings expected to have an individually or collectively material adverse effect on the business, financial condition, or results of operations.
What to watch
-
Material weakness remains unresolved
Internal control over financial reporting was not effective as of the end of the reporting period because remediation of the previously identified material weakness was incomplete. The weakness reflects insufficient accounting-department resources for reviewing manual journal entries, general-ledger reconciliations, financial-statement preparation, and non-routine transactions.
-
Remediation may require added resources
Management stated that, given its limited resources, the company will need to increase its accounting department in the future to fully remediate the weakness; the filing does not provide a completion date.
-
No material risk-factor update
The filing states that the risk factors in the 2026 Annual Report on Form 10-K remain current in all material respects, while also warning that known and unknown risks could cause historical results not to be reliable indicators of future performance.
Management's outlook
The provided 10-Q excerpt contains no quantitative revenue, EPS, margin, cash-flow, or operating outlook. No guidance direction was disclosed.
Earlier filings 4
10-Q · March 11, 2026
Alzamend Neuro, Inc. reported a significant operational loss for the third quarter of fiscal 2026, with no revenue generated during the period. Adjusted EPS improved to -$0.58 compared to -$1.75 year-over-year,…
10-Q · December 9, 2025
Alzamend Neuro's Q2 results for fiscal year 2025 reflect a significant improvement in earnings dynamics despite generating no revenue. The net loss decreased to $1.0 million from $1.4 million, translating to a…
10-Q · September 10, 2025
Alzamend Neuro, Inc. reported a quarterly net loss of $2.7 million with zero revenue for the three months ended July 31, 2025, maintaining the trend from the previous year. Operating expenses rose significantly due to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.